Key Takeaway: Arimoclomol has been shown to upregulate genes associated with the coordinated lysosomal expression and regulation (CLEAR) network. This finding was presented at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025, highlighting its potential implications for metabolic disorders. The research emphasizes the importance of lysosomal function in cellular health.
Price reaction · baseline $8.33 (2025-09-08 close) · hit pre-market · 1 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows potential in gene expression regulation.
The findings contribute to understanding lysosomal functions.
Research presented at a significant international congress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol upregulates expression of genes belonging to the coordinated lysosomal expression and regulation (CLEAR) network
International Congress of Inborn Errors of Metabolism (ICIEM) 2025 - 09/04/2025
Download PDF
Download PDF
Frequently Asked Questions
What is the CLEAR network?
The CLEAR network refers to a set of genes involved in lysosomal expression and regulation.
Where was the research on Arimoclomol presented?
The research was presented at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025.
What is the significance of Arimoclomol's findings?
The findings suggest Arimoclomol may enhance gene expression related to lysosomal functions.